Equities analysts expect that Quanterix Corp (NASDAQ:QTRX) will report sales of $8.52 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Quanterix’s earnings, with the highest sales estimate coming in at $8.62 million and the lowest estimate coming in at $8.40 million. The business is scheduled to announce its next quarterly earnings report on Friday, November 9th.
On average, analysts expect that Quanterix will report full year sales of $34.55 million for the current fiscal year, with estimates ranging from $34.10 million to $35.09 million. For the next financial year, analysts expect that the firm will post sales of $50.02 million per share, with estimates ranging from $49.16 million to $50.89 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Quanterix.
Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). The firm had revenue of $8.64 million during the quarter, compared to the consensus estimate of $7.92 million.
Shares of NASDAQ QTRX traded down $0.71 during mid-day trading on Tuesday, reaching $19.44. 1,620 shares of the company’s stock were exchanged, compared to its average volume of 92,445. The firm has a market cap of $412.16 million and a P/E ratio of -2.43. Quanterix has a twelve month low of $13.00 and a twelve month high of $24.81.
In related news, Chairman E Kevin Hrusovsky sold 17,909 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $14.53, for a total transaction of $260,217.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 31.60% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new position in shares of Quanterix during the first quarter worth about $129,000. Acadian Asset Management LLC bought a new position in shares of Quanterix during the second quarter worth about $117,000. First Republic Investment Management Inc. bought a new position in shares of Quanterix during the second quarter worth about $235,000. Bank of New York Mellon Corp bought a new position in shares of Quanterix during the second quarter worth about $312,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Quanterix during the first quarter worth about $374,000. Institutional investors and hedge funds own 49.14% of the company’s stock.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Further Reading: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.